260
Participants
Start Date
December 14, 2020
Primary Completion Date
October 30, 2027
Study Completion Date
October 30, 2027
FS222
Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.
RECRUITING
Calvary Mater Newcastle, Waratah
RECRUITING
One Clinical Research Perth, Perth
RECRUITING
Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Madrid
RECRUITING
Hospital Universitario 12 De Octubre, Madrid
RECRUITING
NEXT - Hospital Universitario Quironsalud Madrid, Madrid
RECRUITING
Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda
RECRUITING
Clinica Universidad Navarra, Pamplona
RECRUITING
Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria
RECRUITING
Universitary Hospital Virgen Macarena, Seville
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
SLK Kliniken Heilbronn GmbH, Heilbronn
RECRUITING
Prof Dr I Chiricuta Institute of Oncology, Cluj-Napoca
RECRUITING
Arensia Exploratory Medicine, LLC, Tbilisi
RECRUITING
Radboud Universitair Medisch Centrum, Nijmegen
RECRUITING
Centrum Medyczne Poznan - PRATIA - PPDS, Poznan
RECRUITING
MCM Krakow - PRATIA - PPDS, Krakow
RECRUITING
Prof. Dr. Alexandru Trestioreanu Oncologic Institute, Bucharest
RECRUITING
NEXT - Hospital Quironsalud Barcelona, Barcelona
RECRUITING
Hospital Universitari Vall D'Hebron, Barcelona
RECRUITING
Hospital Clinic de Barcelona, Barcelona
RECRUITING
Institut Catala d'Oncologia de Badalona, Barcelona
invoX Pharma Limited
INDUSTRY